admin – page 10 – eisai china lnc.-威尼斯人888

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that it has entered into a business alliance agreement for exclusive development and commercialization of a cognitive function test – cogstate brief battery (cbb) – developed by cogstate ltd. (headquarters: australia, “cogstate”), in japan as a digital tool for self-assessment of cognitive function (classified as miscellaneous goods).

on august 7, 2019, eisai china inc. was invited to participate in a cpc sub-branch co-construction campaign in zhenping organized and arranged by the school of pharmacy of china pharmaceutical university.  seventeen people, including shiying zhang, party secretary of school of pharmacy, yan huang, deputy party secretary and other relevant leaders from china pharmaceutical university, ningbang wang, deputy director of jiangning high-tech park administrative committee, wei guo, chief physician and director of the geriatric endocrinology department of shaanxi provincial people’s hospital, wei cui, chief physician and  director of  department of geriatric endocrinology of first affiliated hospital of xi’an jiaotong university, xiaojing zhang, director of the general practice department and emergency treatment department of second affiliated hospital of xi’an jiaotong university, as well as xiongwei gu party branch secretary and head of internal audit department of eisai china inc., came to zhenping.  the co-construction campaign at this time mainly included: the drug donation by eisai china inc., experts’ free clinic services, “rational drug use” lectures, hierarchical diagnosis and treatment, transfer treatment, academic exchanges, etc.

eisai co.,ltd.(headquarters: tokyo, ceo: haruo naito, “eisai”) announced the presentation and discussion  about the treatment, including oral beta amyloid cleaving enzyme (bace) inhibitor elenbecestat* research data on alzheimer’s disease (ad), were given in the aaic’s focused topic session “discussion of bacei trial findings: challenges and opportunities” at the alzheimer’s association international conference (aaic) held in los angeles, california, united states, from july 14 to 18, 2019. in addition, eisai held a symposium focused on the rationale and opportunities for drug development for pre-clinical ad.

eisai co.,ltd.(headquarters: tokyo, ceo: haruo naito, “eisai”) announced its latest research on evaluation about correlation of amyloid beta (aβ) in plasma and in cerebrospinal fluid (csf) by high precision measurement with the newly developed automated protein assay system, jointly developed with sysmex corporation (headquarters: hyogo, chairman and ceo: hisashi ietsugu, “sysmex”), using full-automated immunoassay system hiscltm*1 series for creating the simplified diagnosis of alzheimer’s disease (ad) with blood was presented at the alzheimer’s association international conference (aaic) held in los angeles, california, united states, from july 14 to 18, 2019. (poster presentation no.: p4-548)

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that eisai received new drug approval for eisai’s in-house developed anticancer agent eribulin mesylate (halaven®) for use in the treatment of patients with locally advanced or metastatic breast cancer, previously treated with at least two prior chemotherapy regimens, including an anthracycline and a taxane, from the china national medical products administration (nmpa).